Alisertib
Tier C — Watch / tradeAlisertib
Targets：AURKA
Indications (approved)：Breast cancer, Metastatic breast cancer, Small cell lung cancer, Solid tumour, Head and neck squamous cell carcinoma, 横纹肌样瘤, 畸胎瘤, Non-small cell lung cancer
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ALISE-006 | 869367-33-9 | (Z)-8-chloro-4-((dimethylamino)methylene)-1-(2-fluoro-6-methoxyphenyl)-3H-benzo[c]azepin-5(4H)-one |
| ALISE-011 | 50-01-1 | guanidine hydrochloride |
| ALISE-012 | 1499168-20-5 | 9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-amine |
| ALISE-013 | 72135-36-5Available | 4-bromo-2-methoxybenzoic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| ALISE-007 | 1028486-08-9 | 4-guanidino-2-methoxybenzoic acid hydrochloride |
| ALISE-014 | 1494680-64-6 | 5-chloro-3-(2-fluoro-6-methoxyphenyl)isobenzofuran-1(3H)-one |
| ALISE-015 | 1497256-70-8 | 2-(5-chloro-3-(2-fluoro-6-methoxyphenyl)-1-hydroxy-1,3-dihydroisobenzofuran-1-yl)acetonitrile |
| ALISE-016 | 1497256-72-0 | (E)-2-(5-chloro-3-(2-fluoro-6-methoxyphenyl)-1-hydroxy-1,3-dihydroisobenzofuran-1-yl)-3-(dimethylamino)acrylonitrile |
| ALISE-017 | 1497256-75-3 | 4-((4-(4-chloro-2-((2-fluoro-6-methoxyphenyl)(hydroxy)methyl)phenyl)-5-cyanopyrimidin-2-yl)amino)-2-methoxybenzoic acid |
| ALISE-018 | - | 4-((5-(aminomethyl)-4-(4-chloro-2-((2-fluoro-6-methoxyphenyl)(hydroxy)methyl)phenyl)pyrimidin-2-yl)amino)-2-methoxybenzoic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| ALISE-001 | 28910-83-0 | (2-amino-5-chlorophenyl)(2,6-difluorophenyl)methanone |
| ALISE-002 | 869365-97-9 | (5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone |
| ALISE-003 | 1233025-91-6 | (5-chloro-2-iodophenyl)(2-fluoro-6-methoxyphenyl)methanone |
| ALISE-004 | 92136-39-5 | tert-butyl prop-2-yn-1-ylcarbamate |
| ALISE-005 | 869366-70-1 | tert-butyl (3-(4-chloro-2-(2-fluoro-6-methoxybenzoyl)phenyl)prop-2-yn-1-yl)carbamate |
| ALISE-006 | 869367-33-9 | (Z)-8-chloro-4-((dimethylamino)methylene)-1-(2-fluoro-6-methoxyphenyl)-3H-benzo[c]azepin-5(4H)-one |
| ALISE-007 | 1028486-08-9 | 4-guanidino-2-methoxybenzoic acid hydrochloride |
| ALISE-008 | 2450-71-7 | prop-2-yn-1-amine |
| ALISE-009 | 27492-84-8 | methyl 4-amino-2-methoxybenzoate |
| ALISE-010 | 173731-96-9 | 4-guanidino-2-methoxybenzoic acid |
Frequently asked questions
What are the approved indications of Alisertib?
Approved indications include: Breast cancer, Metastatic breast cancer, Small cell lung cancer, Solid tumour, Head and neck squamous cell carcinoma, 横纹肌样瘤, 畸胎瘤, Non-small cell lung cancer.
When does the Alisertib patent expire?
No public expiry year is available for Alisertib yet; this page updates once verified.
How many synthesis routes are recorded for Alisertib?
3 synthesis routes are recorded; the shortest is 2 steps with 2.23 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Alisertib intermediates?
1 intermediate CAS of Alisertib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Alisertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21